The Lambert Initiative is researching the application of phytocannabinoids to assist in the treatment and management of chronic and neuropathic pain.
Cannabis and THC have efficacy against neuropathic pain, however, this is hampered by their side effects. It has been suggested that co-administration with CBD might enhance the analgesic actions of THC and minimise its deleterious side effects. We examined the basis for this phytocannabinoid interaction in a mouse model of neuropathic pain.
Results: We found that THC and CBD reduced neuropathic pain. CBD had no adverse side effects. The 1:1 combination of THC and CBD synergistically reduced neuropathic pain with 100-fold greater efficacy than predicted from an additive interaction. THC also synergistically enhanced the efficacy of current first-line neuropathic pain treatments gabapentin and duloxetine.
This was a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney; the Kolling Institute; Royal North Shore Hospital; the Pain Management Research Institute at the University of Sydney, and the Northern Clinical School at the University of Sydney.